Alkem Labs Share Price: Swiss Deal pakka, Q3 mein Revenue 10.7% bhaga, ₹43 Dividend!

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorIshaan Verma|Published at:
Alkem Labs Share Price: Swiss Deal pakka, Q3 mein Revenue 10.7% bhaga, ₹43 Dividend!
Overview

Alkem Laboratories ne ekdum se do bade announcements kiye hain! Ek toh unhone Swiss medical devices company Occlutech Holding AG mein majority stake kharidne ka deal finalize kiya hai, aur doosra, Q3 FY26 mein unka consolidated revenue **10.7%** badhkar **₹3,737 Crore** ho gaya hai. Plus, **₹43** ka interim dividend bhi de rahe hain.

Alkem ka Global Game Plan: Swiss Deal Done! 🤝

Company ne ek dum bada kadam uthaya hai! Swiss medical devices firm, Occlutech Holding AG, mein majority stake acquire karne ke liye binding term sheet sign kar diya hai. Is deal se Alkem apne MedTech business ko globally expand karne wala hai, especially minimally invasive cardiac implants mein. Ye Alkem ke future growth ke liye ek major booster ho sakta hai.

Results Bhi Aaye, Par Thoda Mix Tha 📊

Ab numbers ki baat karein toh, Q3 FY26 mein Alkem ka consolidated revenue 10.7% year-on-year badhkar ₹37,368.2 million (yaani ₹3,736.82 Crore) tak pahunch gaya. Aur 9 mahine ke period mein bhi revenue 13.1% badha hai.

Par profit ka scene thoda alag hai. Consolidated EBITDA toh 9.0% badhkar ₹8,280 million ho gaya, lekin EBITDA margin thoda sa 22.2% par aa gaya, jo pehle 22.5% tha. Consolidated Net Profit mein bhi bas 1.6% ka jump dikha hai, jo ₹6,360.2 million ho gaya.

Lekin, agar sirf standalone operations ko dekhein toh PBT 4.7% aur PAT 7.9% neeche gira hai. Toh matlab company ka performance overall theek hai, par India mein thoda pressure hai.

International Sales Ki Toofani Tezi! 🚀

Is growth ka bada credit international sales ko jaata hai, jo 26.6% bhag gaye! US mein 18.8% aur non-US markets mein toh 41.6% ki tezi rahi. India sales sirf 5.5% badhi. Toh ye saaf hai ki company abroad mein achha kar rahi hai.

Aur Kya Hai Khaas? Dividend aur Future Plans 💰

Investors ke liye ek achhi khabar yeh hai ki company ₹43 per share ka interim dividend declare kiya hai. Management full-year guidance meet karne ko lekar confident hai. Future mein, March 2026 tak GLP-1 semaglutide launch karne ka plan hai, jo ek bada growth driver ban sakta hai.

Kya Dekhna Hai Aage? 🤔

Ab sabki nazar Occlutech deal ke integration par rahegi. Kya company ise succesfully manage kar paati hai aur MedTech business mein global footprint bana paati hai, ye dekhna interesting hoga. Standalone profitability ka girna bhi ek point hai jise monitor karna hoga. Aur GLP-1 launch kitna successful hota hai, ye bhi crucial rahega.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.